BioSpace News Archive

InnoCare, a leading biopharmaceutical company focusing on drug innovation for cancer and autoimmune diseases, announced the first subject dosed in clinical trial of novel TYK2 inhibitor ICP-332 in China.

InxMed Co., Ltd., a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced the U.S. Food and Drug Administration has granted Fast Track designation to IN10018 for the treatment of platinum-resistant ovarian cancer patients.

Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, reported that after reviewing previously-reported Phase II trial data, the Israeli Ministry of Health has authorized the initiation of a proposed Company-sponsored, multi-center, placebo-controlled, randomized, blinded, Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with acute respiratory distressed syndrome.

Innovent Biologics, Inc. today announced that the sintilimab Phase 3 ORIENT-16 study met its predefined primary endpoint of overall survival (OS).

GeneQuantum Healthcare announced a key appointment to further strengthen GeneQuantum management team.